| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CALU |
| Uniprot No | O43852-1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-311aa |
| 氨基酸序列 | MDLRQFLMCL SLCTAFALSK PTEKKDRVHH EPQLSDKVHN DAQSFDYDHD AFLGAEEAKT FDQLTPEESK ERLGKIVSKI DGDKDGFVTV DELKDWIKFA QKRWIYEDVE RQWKGHDLNE DGLVSWEEYK NATYGYVLDD PDPDDGFNYK QMMVRDERRF KMADKDGDLI ATKEEFTAFL HPEEYDYMKD IVVQETMEDI DKNADGFIDL EEYIGDMYSH DGNTDEPEWV KTEREQFVEF RDKNRDGKMD KEETKDWILP SDYDHAEAEA RHLVYESDQN KDGKLTKEEI VDKYDLFVGS QATDFGEALV R |
| 预测分子量 | 36 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CALU(Calumenin)重组蛋白的虚构参考文献示例，格式为文献名称、作者及摘要概括：
---
1. **文献名称**: *Expression and Functional Analysis of Recombinant Calumenin in Endoplasmic Reticulum Calcium Homeostasis*
**作者**: Zhang L, et al.
**摘要**: 本研究成功构建了人源CALU重组蛋白表达系统(大肠杆菌)，通过His标签纯化获得高纯度蛋白。实验发现重组CALU在体外可结合钙离子，并通过调节内质网钙泵SERCA2活性影响细胞内钙稳态，提示其在内质网应激中的潜在作用。
---
2. **文献名称**: *Calumenin Recombinant Protein Inhibits Platelet Aggregation via Interaction with STIM1/Orai1 Complex*
**作者**: Tanaka K, et al.
**摘要**: 通过哺乳动物细胞表达系统获得功能性CALU重组蛋白，发现其能特异性结合钙通道调控蛋白STIM1/Orai1.抑制血小板内钙信号传导，从而减少血栓形成，为抗凝血药物开发提供新靶点。
---
3. **文献名称**: *Role of Recombinant Calumenin in Cancer Cell Migration: Implications for Metastasis*
**作者**: Gupta S, et al.
**摘要**: 利用昆虫细胞表达系统制备CALU重组蛋白，发现其通过调控整合素β1的折叠和膜定位，抑制乳腺癌细胞迁移和侵袭，表明CULO可能作为抑制肿瘤转移的潜在分子工具。
---
注：以上文献为示例，实际研究中需根据具体数据库(如PubMed、Web of Science)检索真实文献。
**Background of CALU Recombinant Protein**
Calumenin (CALU), a calcium-binding protein belonging to the reticulocalbin family, is primarily localized in the endoplasmic reticulum (ER) and secretory pathways. It features six conserved EF-hand motifs, though only a subset binds calcium, suggesting roles in calcium homeostasis and protein processing. CALU interacts with ER-resident chaperones and enzymes, including vitamin K-dependent γ-glutamyl carboxylase, influencing post-translational modifications critical for coagulation factors (e.g., factors VII, IX) and anticoagulant proteins (e.g., Protein C). This positions CALU as a regulator of hemostasis and thrombotic pathways.
Beyond coagulation, CALU modulates intracellular signaling by binding to proteins like RyR2 (ryanodine receptor 2) in cardiac cells, affecting calcium release and muscle contraction. Its dysregulation is linked to cardiovascular diseases, cancer metastasis, and neurodegenerative disorders, potentially through disrupted calcium signaling or ER stress responses.
Recombinant CALU protein is engineered via heterologous expression systems (e.g., *E. coli* or mammalian cells), enabling studies on its structure-function relationships and mechanistic roles. Purified recombinant CALU serves as a tool to investigate protein-protein interactions, screen drug candidates targeting calcium-related pathologies, and develop diagnostic assays for diseases associated with CALU dysfunction. Recent studies also explore its potential as a biomarker for thrombotic risk or therapeutic target in ER stress-associated conditions.
Overall, CALU recombinant protein bridges basic research and translational applications, offering insights into cellular calcium dynamics and pathways underlying diverse diseases.
×
